S
Sarah Arterburn
Publications - 47
Citations - 6642
Sarah Arterburn is an academic researcher. The author has contributed to research in topics: Liver transplantation & Adefovir. The author has an hindex of 22, co-authored 45 publications receiving 6381 citations.
Papers
More filters
Journal ArticleDOI
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more
TL;DR: In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Journal ArticleDOI
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Stephanos J. Hadziyannis,Nicolaos C. Tassopoulos,E. Jenny Heathcote,Ting-Tsung Chang,George Kitis,Mario Rizzetto,Patrick Marcellin,Seng Gee Lim,Zachary Goodman,Jia Ma,Carol L. Brosgart,Katyna Borroto–Esoda,Sarah Arterburn,Steven L. Chuck +13 more
TL;DR: Treatment with adefovir dipivoxil for up to 240 weeks was well tolerated and produced significant, increasing improvement in hepatic fibrosis, durable suppression of HBV replication, normalization of liver enzymes, and delayed development of resistance.
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
TL;DR: The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produced high rates of SVR12 in patients with advanced liver disease, including those with decompensated cirrhosis before and after liver transplantation.
Journal ArticleDOI
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
TL;DR: In this article, the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuvir, and ribavirin were used to treat chronic hepatitis C virus (HCV) infection in patients with advanced liver disease.
Journal ArticleDOI
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
Stephanos J. Hadziyannis,Nicolaos C. Tassopoulos,E. Jenny Heathcote,Ting-Tsung Chang,George Kitis,Mario Rizzetto,Patrick Marcellin,Seng Gee Lim,Zachary Goodman,Jia Ma,Sarah Arterburn,Shelly Xiong,Graeme Currie,Carol L. Brosgart +13 more
TL;DR: In patients with HBeAg-negative chronic hepatitis B, the benefits achieved from 48 weeks of adefovir dipivoxil were lost when treatment was discontinued, with infrequent emergence of viral resistance.